Table 4. Effect of previous treatment on association of number of likely effective drugs with treatment success—during different phases of treatment.
| n Likely Effective Drugs – Patients Stratified by Treatment History | All Patients Success Versus Fail/Relapse/Death | No Prior MDR Treatment Success Versus Fail/Relapse/Death | Prior MDR Treatment Success Versus Fail/Relapse/Death | ||||||
| n | aOR | (95% CI) | n | aOR | (95% CI) | n | aOR | (95% CI) | |
| Initial phase | |||||||||
| 0–2 | 277 | 1.0 | (reference) | 246 | 1.0 | (reference) | 6 | 1.0 | (reference) |
| 3 | 250 | 1.7 | (1.2–2.5) | 186 | 2.3 | (1.4–2.9) | 16 | ||
| 4 | 542 | 2.7 | (1.9–3.9) | 385 | 3.4 | (2.2–5.2) | 66 | 1.4 | (0.5–3.8) |
| 5 | 900 | 2.8 | (1.7–4.6) | 650 | 2.6 | (1.7–4.0) | 111 | 3.4 | (1.2–9.8) |
| 6+ | 977 | 2.1 | (1.4–3.1) | 515 | 3.1 | (2.0–4.9) | 327 | 1.6 | (0.3–9.1) |
| Continuation phase | |||||||||
| 0–2 | 531 | 1.0 | (reference) | 467 | 1.0 | (reference) | 32 | 1.0 | (reference) |
| 3 | 635 | 5.7 | (3.4–9.7) | 532 | 5.5 | (2.2–13.6) | 46 | 5.5 | (2.3–13.1) |
| 4 | 663 | 5.7 | (3.2–10.0) | 430 | 3.3 | (1.8–6.3) | 89 | 9.1 | (4.4–18.8) |
| 5+ | 608 | 7.0 | (5.1–9.7) | 265 | 4.6 | (1.5–14.0) | 211 | 13.7 | (8.2–23.0) |
Likely effective, drugs to which isolate susceptible in laboratory testing. n, number of patients in subgroup of interest. aOR, adjustment described in footnotes for Table 3. Success, defined as cure or treatment completion; see Methods for definitions. Initial intensive phase, period when injectable given. Continuation phase, period when no injectable given. Only 18 studies provided information regarding drug susceptibility testing and the number of drugs in the initial phase, while only 15 of these described the number of drugs in the continuation phase. Bold, estimates are significantly different from the reference group.